File Download

There are no files associated with this item.

  Links for fulltext
     (May Require Subscription)
Supplementary

Article: A randomized comparison of side effects and patient convenience between Cyclogest® suppositories and Endometrin® tablets used for luteal phase support in IVF treatment

TitleA randomized comparison of side effects and patient convenience between Cyclogest® suppositories and Endometrin® tablets used for luteal phase support in IVF treatment
Authors
Issue Date2007
PublisherElsevier Ireland Ltd. The Journal's web site is located at http://www.elsevier.com/locate/ejogrb
Citation
European Journal Of Obstetrics Gynecology And Reproductive Biology, 2007, v. 131 n. 2, p. 182-188 How to Cite?
AbstractObjective: This study compared side effects and patient convenience of vaginal progesterone suppositories (Cyclogest®) and vaginal progesterone tablets (Endometrin®) used for luteal phase support in in vitro fertilization/embryo transfer (IVF/ET) cycles using pituitary downregulation. Study design: One hundred and thirty-two infertile patients were randomized on the day of ET by a computer-generated randomization list in sealed envelopes to receive either Cyclogest® 400 mg or Endometrin® 100 mg twice daily for 14 days. On days 6 and 16 after ET, they rated side effects and patient convenience into four grades: none, mild, moderate and severe by completing a questionnaire. Results: No significant differences in perineal irritation were found on days 6 and 16 after ET between the two groups, although there was a trend of fewer patients with perineal irritation in the Endometrin® group. Significantly more patients in the Endometrin® group had difficulty of administration on day 6 after ET. There were no differences in the hormonal profile on day 6 after ET and IVF outcomes between the two groups. Conclusion: There was no difference in perineal irritation after the use of Cyclogest® suppositories or Endometrin® tablets for luteal phase support although more patients found administration of Endometrin® tablets difficult. © 2006 Elsevier Ireland Ltd. All rights reserved.
Persistent Identifierhttp://hdl.handle.net/10722/173320
ISSN
2015 Impact Factor: 1.662
2015 SCImago Journal Rankings: 0.808
ISI Accession Number ID
References

 

DC FieldValueLanguage
dc.contributor.authorNg, EHYen_US
dc.contributor.authorChan, CCWen_US
dc.contributor.authorTang, OSen_US
dc.contributor.authorHo, PCen_US
dc.date.accessioned2012-10-30T06:29:17Z-
dc.date.available2012-10-30T06:29:17Z-
dc.date.issued2007en_US
dc.identifier.citationEuropean Journal Of Obstetrics Gynecology And Reproductive Biology, 2007, v. 131 n. 2, p. 182-188en_US
dc.identifier.issn0301-2115en_US
dc.identifier.urihttp://hdl.handle.net/10722/173320-
dc.description.abstractObjective: This study compared side effects and patient convenience of vaginal progesterone suppositories (Cyclogest®) and vaginal progesterone tablets (Endometrin®) used for luteal phase support in in vitro fertilization/embryo transfer (IVF/ET) cycles using pituitary downregulation. Study design: One hundred and thirty-two infertile patients were randomized on the day of ET by a computer-generated randomization list in sealed envelopes to receive either Cyclogest® 400 mg or Endometrin® 100 mg twice daily for 14 days. On days 6 and 16 after ET, they rated side effects and patient convenience into four grades: none, mild, moderate and severe by completing a questionnaire. Results: No significant differences in perineal irritation were found on days 6 and 16 after ET between the two groups, although there was a trend of fewer patients with perineal irritation in the Endometrin® group. Significantly more patients in the Endometrin® group had difficulty of administration on day 6 after ET. There were no differences in the hormonal profile on day 6 after ET and IVF outcomes between the two groups. Conclusion: There was no difference in perineal irritation after the use of Cyclogest® suppositories or Endometrin® tablets for luteal phase support although more patients found administration of Endometrin® tablets difficult. © 2006 Elsevier Ireland Ltd. All rights reserved.en_US
dc.languageengen_US
dc.publisherElsevier Ireland Ltd. The Journal's web site is located at http://www.elsevier.com/locate/ejogrben_US
dc.relation.ispartofEuropean Journal of Obstetrics Gynecology and Reproductive Biologyen_US
dc.rightsEuropean Journal of Obstetrics & Gynecology and Reproductive Biology. Copyright © Elsevier Ireland Ltd.-
dc.subject.meshAdulten_US
dc.subject.meshDose-Response Relationship, Drugen_US
dc.subject.meshEstradiol - Blooden_US
dc.subject.meshFemaleen_US
dc.subject.meshFertilization In Vitro - Methodsen_US
dc.subject.meshHumansen_US
dc.subject.meshInfertility, Female - Drug Therapy - Physiopathologyen_US
dc.subject.meshLuteal Phase - Drug Effectsen_US
dc.subject.meshPituitary Gland - Drug Effects - Physiopathologyen_US
dc.subject.meshProgesterone - Administration & Dosage - Pharmacology - Therapeutic Useen_US
dc.subject.meshSuppositories - Adverse Effectsen_US
dc.subject.meshTime Factorsen_US
dc.subject.meshVaginal Creams, Foams, And Jellies - Adverse Effectsen_US
dc.titleA randomized comparison of side effects and patient convenience between Cyclogest® suppositories and Endometrin® tablets used for luteal phase support in IVF treatmenten_US
dc.typeArticleen_US
dc.identifier.emailNg, EHY:nghye@hkucc.hku.hken_US
dc.identifier.emailHo, PC:pcho@hku.hken_US
dc.identifier.authorityNg, EHY=rp00426en_US
dc.identifier.authorityHo, PC=rp00325en_US
dc.description.naturelink_to_subscribed_fulltexten_US
dc.identifier.doi10.1016/j.ejogrb.2006.07.023en_US
dc.identifier.pmid16920249-
dc.identifier.scopuseid_2-s2.0-33947501992en_US
dc.identifier.hkuros133344-
dc.relation.referenceshttp://www.scopus.com/mlt/select.url?eid=2-s2.0-33947501992&selection=ref&src=s&origin=recordpageen_US
dc.identifier.volume131en_US
dc.identifier.issue2en_US
dc.identifier.spage182en_US
dc.identifier.epage188en_US
dc.identifier.isiWOS:000246159400013-
dc.publisher.placeIrelanden_US
dc.identifier.scopusauthoridNg, EHY=35238184300en_US
dc.identifier.scopusauthoridChan, CCW=26643394500en_US
dc.identifier.scopusauthoridTang, OS=36881248500en_US
dc.identifier.scopusauthoridHo, PC=7402211440en_US

Export via OAI-PMH Interface in XML Formats


OR


Export to Other Non-XML Formats